IM-250 is a novel, orally available, selective HSV-helicase primase inhibitor. Helicase primase inhibitors block unwinding of DNA in the replication fork during DNA-replication by a potentially uncompetitive mechanism of action. IM-250 binds to the helicase primase complex of HSV-1 and -2, blocking DNA-replication and therefore, preventing replication of the virus.
Significant preclinical antiviral efficacy has been demonstrated for IM-250. A favourable pharmacokinetic and safety profile was established in animal models. Results were published in top tier peer reviewed journals. The clinical program for IM-250 has successfully been initiated.
Reprint of the Science
Translational Medicine Publication
| Indications | Development | Status |
|---|---|---|
|
Genital herpes (oral)
Suppressive therapy/latency
Life-long infection, recurring genital ulcers and pain
|
|
Phase 1b
|
|
Herpes encephalitis (IV)
Rare, life threatening brain inflammation caused by HSV
|
|
Phase 1
|
|
Genital herpes (oral)
Episodic therapy
|
|
|
|
Herpes labialis
|
|
|
| Development | Status |
|---|---|
|
Indications
Genital herpes (oral) Suppressive therapy/latency Life-long infection, recurring genital ulcers and pain |
Phase 1b
|
|
Indications
Herpes encephalitis (IV) Rare, life threatening brain inflammation caused by HSV |
Phase 1
|
|
Indications
Genital herpes (oral) Episodic therapy |
|
|
Indications
Herpes labialis |
|
Discovery Candidate IND-enabling Phase-1a Phase-1b Phase-2 Phase-3
Suppressive therapy/latency
Life-long infection, recurring genital ulcers and pain
Status
Discovery Candidate IND-enabling Phase-1a Phase-1b Phase-2 Phase-3
Rare, life threatening brain inflammation caused by HSV
Status
Discovery Candidate IND-enabling Phase-1a Phase-1b Phase-2 Phase-3
Discovery Candidate IND-enabling Phase-1a Phase-1b Phase-2 Phase-3